Fig. 5 | Scientific Reports

Fig. 5

From: Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial

Fig. 5

Change of PROMIS scores instrument items in PCSK9i at baseline, week 12, and week 48. (a) Change of physical health; (b) Change of physical function; (c) Change of fatigue; (d) Change of pain intensity; (e) Change of overall quality of life; (f) Change of mental health; (g) Change of satisfaction with social activities; (h) Change of emotional problems.

Back to article page